Marketing analysis of levocarnitine and glucosamine preparations

L. Davtian¹, A. Voronkina², O. Khomych¹, O. Toziuk², D. Voronkin³
¹Department of Pharmaceutical Technology and Biopharmacy, Shupyk National Medical Academy of Postgraduate Education, Kyiv, ²Department of Pharmacy, National Pirogov Memorial Medical University, Vinnytsya, ³Pharmaceutical Corporation “Yuria-Pharm,” Kiev, Ukraine

Abstract

Aim: For the problem of the struggle of the human body with extreme strains, it is advisable to use active pharmaceutical ingredients that would directly participate in the metabolism having an actoprotective effect without exhausting the body. Levocarnitine and glucosamine have such properties. In this work was studied the development of the pharmaceutical market of Ukraine and the definition of market needs for combined and monopreparations of levocarnitine and glucosamine. Materials and Methods: The analysis of the market from January 2015 to September 2017 showed a significant increase in the sales of glucosamine hydrochloride and levocarnitine products, both in natural and monetary equivalents. Thus, the analysis of the data proves that the anabolic and frigoprotective properties of glucosamine have not received enough attention. The statistical data suggest that there is a growing market demand for levocarnitine for oral administration. Results: The ratio of the sales of glucosamine hydrochloride for injections and for oral use began to change when one of the Ukrainian drug manufacturers came out on the market with generic glucosamine hydrochloride for oral use. The changes in the price of one dose of glucosamine hydrochloride for oral use are due to the growth of the market share occupied by Ukrainian producers in this segment too. Such a shift in sales toward Ukrainian drugs contributes to the overall increase in the availability of drugs. Conclusions: Analysis of Ukrainian market of the glucosamine and levocarnitine preparations showed uneven distribution of foreign and domestic manufacturers.

Key words: Glucosamine hydrochloride, levocarnitine, market analysis, monopreparations

INTRODUCTION

The problem of the struggle of the human body with extreme strains that ever occur in the way of the person is still relevant nowadays. Meanwhile in Ukraine, ATC group A14B “nonsteroidal anabolic drugs for system use” contains only two registered international non-proprietary names of medicinal substances.[¹,²] Those drugs increase resistance to of a certain part of the body to strain when applied but may have side effects elsewhere. It is advisable to use active pharmaceutical ingredients that would directly participate in the metabolism and would have an actoprotective effect without exhausting the body and without significant side effects.[³] Levocarnitine and glucosamine have such properties. Their combination can be used in traumatology to improve the working capacity of people with inflammatory diseases of the joints and also can be widely used in the production of functional foods for people with high physical and psychoemotional loads, particularly for athletes.[⁴-⁷] Existing research on the use of levocarnitine demonstrates its effect on increased load tolerance, as well as anabolic, cardioprotective, and antianemic effects.[⁵,⁶,⁸] According to various literary sources, levocarnitine is classified into the groups of actoprotectors, antihypoxants, or non-steroidal anabolic drugs.[⁵-⁸] Glucosamine is widely used for the treatment of arthrosis and osteoarthritis, while recent studies demonstrate its anti-inflammatory, anabolic, and frigoprotective activity. [⁴,⁹] The purpose of this work was to study the development of the pharmaceutical market of Ukraine for preparations of levocarnitine and glucosamine, as well as the definition of market needs for combined and monopreparations with the indicated active pharmaceutical ingredients.

Address for correspondence:
Alyona Voronkina, Department of Pharmacy, National Pirogov Memorial Medical University, Pirogov str., 56, Vinnytsya, Ukraine. Tel.: +38050-461-42-61. E-mail: algol2808@gmail.com

Received: 05-05-2018
Revised: 28-10-2018
Accepted: 22-11-2018
MATERIALS AND METHODS

Chemicals and Drugs

Levocarnitine and glucosamine hydrochloride was purchased from Sigma Chemical Co., from HiMedia Pvt., Ltd. All other chemicals and reagents were analytical grade.

Data collection

The materials for the study were the data of the State Register of Drugs of Ukraine (collected on October 1, 2017) [1] regarding the registered medicinal products containing levocarnitine and glucosamine hydrochloride (data included the information about the name and composition of the medicinal products, pharmaceutical form, manufacturer, and applicant), as well as information on the database “Morion” and Proxima Research for 2015–2017 [10] on the volumes of the sales of monopreparations of levocarnitine and glucosamine hydrochloride of various forms of the production measured both in financial terms (in Ukrainian Hryvnia [UAH] and U.S. dollar [USD]) and total quantity (packs).

For the marketing analysis, the monthly dynamics of the sales of processed medicines, the dynamics of changes in the demand balance for preparations of various forms of release, the change in the average packing price, and the dose of drugs were analyzed.

RESULTS

According to the State Register of Drugs, 23 drugs containing carnitine have been registered in Ukraine, five of them are substances, and 18 are medicines. 14 drugs contain levocarnitine, two are combined medications, and 12 are monopreparations. Most of these drugs - 12 - belong to the ATC group A16AA01 “Amino acids and their derivatives.” Nine are solutions for injections, five are drugs for oral use, four of which are solutions for oral administration, and one - tablets.

There are two brands of drugs for carnitine for injection and two solid combined drugs in Ukraine. No liquid drugs containing carnitine are produced in Ukraine.

According to the State Register of Drugs in Ukraine, 38 registration certificates for glucosamine preparations are valid. Of these, five are substances and four are in bulk drugs. Of the 29 glucosamine medicines available on the market, 10 are glucosamine monopreparations, of which five are in the form of powder for oral solution, three are solutions for injections, and one is in the form of tablets. Of the 19 combined drugs containing glucosamine, one is cream and the rest are solid dosage forms in the form of capsules (six drugs) and tablets (12 drugs). Most of the glucosamine containing combined drugs found on the market are combinations of glucosamine and chondroitin (12 medicines), or glucosamine, chondroitin, and nonsteroidal anti-inflammatory drugs (NSAIDs) (diclofenac or ibuprofen) (five medicines). All drugs containing glucosamine are classified by the State Register of Drugs to the ATC group M “Drugs affecting the musculoskeletal system.” 20 of them are attributed to the ATC group M01 “anti-inflammatory and antirheumatic drugs,” and nine drugs to the ATC group M09 “Other drugs affecting the musculoskeletal system.”

Thus, the statistics of the State Register of Drugs proves that the anabolic and frigoprotective properties of glucosamine have not received enough attention, while manufacturers continue to introduce on the market glucosamine generic drugs and its new combinations with NSAIDs for the treatment of diseases of the musculoskeletal system.

DISCUSSION

The next stage of the investigation was the analysis of the market development dynamics for monopreparations of the glucosamine and levocarnitine using monetary and natural equivalents [11,12].

Monthly sales volumes show that despite the continuing general tendency of the market of growing sales volumes in UAH and decreasing volumes-- in packs and USD equivalents, sales of levocarnitine drugs increased significantly in 2015–2017 [Figures 1 and 2]. It should be noted that the greatest increase in the volume of pharmacy sales in packs for levocarnitine was observed during the past year (from September 2016 to September 2017) [Figure 1].

It is important to note that the growth in sales of levocarnitine, both in money and in packs, occurred mainly due to the general increase in sales of levocarnitine for oral administration. This is particularly evident in USD sales. This is evidenced by the gradual increase in the proportion of sales (in UAH, USD, and in packages) of levocarnitine for oral administration from 60% to 70% [Figure 3] and from 55% to 65% [Figure 4] in both natural and monetary terms, respectively.

The average cost of one pack of the levocarnitine drugs (UAH) in recent years has practically not changed and amounted to 205 ± 11 UAH (8.47 ± 0.82 USD) for drugs for oral administration and 261 ± 18 UAH (10.78 ± 1.42 USD) for solutions for injections. For the analyzed period, the total cost of one package of the levocarnitine preparations in USD fell by 26%. By 21% for oral solutions and 32% for drugs for injections, which is mainly due to significant currency exchange rate fluctuations during 2015 [Figure 5].
Davtian, et al.: Marketing analysis of levocarnitine and glucosamine preparations

**Figure 1:** Dynamics of monopreparations of the levocarnitine sales, 2015–2017, packs

**Figure 2:** Dynamics of monopreparations of the levocarnitine sales, 2015–2017, USD

**Figure 3:** Dynamics of proportion of the share of sales (packs) for levocarnitine for oral use and for injections, %

**Figure 4:** Dynamics of proportion of the share of sales (USD) for levocarnitine for oral use and for injections, %
Consequently, the Statistical Data Suggest that there is a Growing Market Demand for Levocarnitine for Oral Administration\[13,14]\]

A similar analysis was carried out on the development of the market for glucosamine hydrochloride monoforms during 2015–2017 presented as a powder for oral solution preparation of 1.5 g glucosamine hydrochloride in a sachet of four manufacturers and glucosamine hydrochloride solution 200 mg/ml in 2 ml ampoules of two manufacturers.

The analysis of the market from January 2015 to September 2017 showed a significant increase in the sales of glucosamine hydrochloride products, both in natural [Figure 6] and monetary terms: UAH and USD [Figure 7] equivalents. In the monetary equivalent, the main part of the increase was injections: Their sales increased 2.53 times in UAH (1.53 times in USD). Meanwhile, in natural terms (the number of packages), the highest growth - 2.88 times showed preparations of glucosamine hydrochloride for oral administration, for which sales in money terms increased by 1.96 and 1.19 times in UAH and USD equivalents, respectively. The ratio of the sales of glucosamine hydrochloride for injections and for oral use (packs) began to change in early...
2016 when one of the leading Ukrainian drug manufacturers came out on the market with their product - generic glucosamine hydrochloride for oral use [Figure 8]. The overall dynamics of the gradual increase in the proportion of drugs for injections was interrupted, and by September 2017, the proportion of glucosamine hydrochloride preparations for oral administration increased from 21% to 35%.

At the same time, in monetary terms, the proportion of medicinal products glucosamine hydrochloride in various forms during
Davtian, et al.: Marketing analysis of levoсarnitine and glucosamine preparations

International Journal of Green Pharmacy
• Oct-Dec 2018 (Suppl) • 12 (4) | S813

this period did not change significantly, and after the exchange rate, fluctuations in early 2015 were about 65% for drugs for injections and 35% for drugs for oral administration.

This discrepancy of market shares in cash and in packs is mainly due to a significant change in the average price per pack of glucosamine hydrochloride for oral use [Figure 11], which for the analyzed period [Figure 10] decreased from 37.24 USD (588.91 UAH) to 15.36 USD (401.27 UAH).

The change in the average pack’s price was due to the two factors: The decrease in the number of doses of the drugs in the package and the decrease in the cost of one dose of the drugs. Decrease in the average cost of a single dose of glucosamine hydrochloride for oral administration from 1.86 USD (29.44 UAH) to 0.74 USD (19.3 UAH) [Figure 9] contributed to the overall dynamics of demand growth for oral glucosamine hydrochloride preparations, which was reflected in the growth of the number of sold doses of the drugs for the analyzed period. For preparations for oral administration, the number of realized doses of the drugs increased almost 3 times. At the same time, the number of doses of the drugs for injection increased only 1.57 times and the average cost ranged slightly and was 2.62 ± 0.21 USD (64.20 ± 8.35 UAH).

The changes in the price of one dose of the glucosamine hydrochloride for oral use are due to the growth of the market share occupied by Ukrainian producers in this segment [Figure 12] from 25% in early 2015 to 60% at the end of 2017. Such a shift in sales toward drugs contributes to the overall increase in the availability of drugs[15] The cost of drugs is lower than similar imported drugs, in addition, the emergence of lower priced drugs at the market contributed to a decrease in the average price and on imported medicines.[16]

CONCLUSIONS

1. Analysis of Ukrainian market of the glucosamine and levocarnitine preparations showed uneven distribution of foreign and domestic manufacturers.

2. Monthly sales analysis in both physical and monetary equivalents showed an increase in demand for levocarnitine and glucosamine for oral administration in the period from 2015 to 2017; meanwhile, no drugs containing both medicinal matters were found on the market.

3. The anabolic and frigoprotective properties of glucosamine have not received enough attention, while manufacturers continue to introduce new combinations of glucosamine with NSAIDs for the treatment of diseases of the musculoskeletal system.

4. The analysis of the market demonstrated the overall positive impact of the market entry of Ukrainian manufacturers, which is manifested by a decrease in the average cost of packaging and dose of drugs, and increased availability of the medicines.

REFERENCES


7. Reuter SE, Evans AM. Carnitine and acylcarnitines.

Source of Support: Nil. Conflict of Interest: None declared.